These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27252258)

  • 1. Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE.
    Biesen R; Rose T; Hoyer BF; Alexander T; Hiepe F
    Lupus; 2016 Jul; 25(8):823-9. PubMed ID: 27252258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
    Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
    Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies to C-reactive protein in incomplete lupus and systemic lupus erythematosus.
    Jung JY; Koh BR; Kim HA; Jeon JY; Suh CH
    J Investig Med; 2014 Aug; 62(6):890-3. PubMed ID: 24896736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus.
    Rose T; Grützkau A; Hirseland H; Huscher D; Dähnrich C; Dzionek A; Ozimkowski T; Schlumberger W; Enghard P; Radbruch A; Riemekasten G; Burmester GR; Hiepe F; Biesen R
    Ann Rheum Dis; 2013 Oct; 72(10):1639-45. PubMed ID: 23117242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies.
    Jucaud V; Ravindranath MH; Terasaki PI; Morales-Buenrostro LE; Hiepe F; Rose T; Biesen R
    Clin Exp Immunol; 2016 Mar; 183(3):326-40. PubMed ID: 26440212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus.
    Smith MA; Chiang CC; Zerrouki K; Rahman S; White WI; Streicher K; Rees WA; Schiffenbauer A; Rider LG; Miller FW; Manna Z; Hasni S; Kaplan MJ; Siegel R; Sinibaldi D; Sanjuan MA; Casey KA
    Sci Rep; 2020 Mar; 10(1):4462. PubMed ID: 32157125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.
    Hui-Yuen JS; Gartshteyn Y; Ma M; O'Malley T; Conklin J; Eichenfield AH; Imundo LF; Dervieux T; Askanase AD
    Lupus; 2018 Dec; 27(14):2262-2268. PubMed ID: 30376789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic criteria for systemic lupus erythematosus: a critical review.
    Yu C; Gershwin ME; Chang C
    J Autoimmun; 2014; 48-49():10-3. PubMed ID: 24461385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for systemic lupus erythematosus.
    Herbst R; Liu Z; Jallal B; Yao Y
    Int J Rheum Dis; 2012 Oct; 15(5):433-44. PubMed ID: 23083033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of biomarkers in the management of children with lupus.
    Binder E; Edelbauer M
    Curr Rheumatol Rep; 2013 Mar; 15(3):312. PubMed ID: 23355230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-ribosomal P antibodies are associated with elevated circulating IFNα and IL-10 levels in systemic lupus erythematosus patients.
    Mozo L; López P; Caminal-Montero L; Rodríguez-Carrio J; Suárez A
    Lupus; 2014 Dec; 23(14):1477-85. PubMed ID: 25107939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher interferon score and normal complement levels may identify a distinct clinical subset in children with systemic lupus erythematosus.
    Tesser A; de Carvalho LM; Sandrin-Garcia P; Pin A; Pastore S; Taddio A; Roberti LR; de Paula Queiroz RG; Ferriani VPL; Crovella S; Tommasini A
    Arthritis Res Ther; 2020 Apr; 22(1):91. PubMed ID: 32334613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
    Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy.
    Doria A; Iaccarino L; La Montagna G; Mathieu A; Piga M; Galeazzi M; Iuliano A; Maurel FB; Garofano AM; Perna AG; Porcasi RE
    Clin Exp Rheumatol; 2015; 33(3):375-84. PubMed ID: 26005879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACR classification criteria for systemic lupus erythematosus: complement components.
    Nived O; Sturfelt G
    Lupus; 2004; 13(11):877-9. PubMed ID: 15580986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum anti-lipocalin 2 IgG is a novel biomarker in the diagnosis of systemic lupus erythematosus.
    Li YN; Hu FL; Dai YJ; Li R; Ma XX; Du Y; Feng M; Jia Y; Zhang CF; Zhu L; Ascherman DP; Li ZG
    Lupus; 2014 Aug; 23(9):868-75. PubMed ID: 24704774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus.
    Amezcua-Guerra LM; Springall R; Arrieta-Alvarado AA; Rodríguez V; Rivera-Martinez E; Castillo-Martinez D; Bojalil R
    Clin Lab; 2011; 57(7-8):607-13. PubMed ID: 21888025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canine systemic lupus erythematosus: new insights and their implications.
    Jones DR
    J Comp Pathol; 1993 Apr; 108(3):215-28. PubMed ID: 8315051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes.
    Karageorgas TP; Tseronis DD; Mavragani CP
    J Biomed Biotechnol; 2011; 2011():273907. PubMed ID: 22162633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Concentrations of Serum Immunoglobulin Free Light Chains in Systemic Lupus Erythematosus Patients in Relation to Disease Activity, Inflammatory Status, B Cell Activity and Epstein-Barr Virus Antibodies.
    Draborg AH; Lydolph MC; Westergaard M; Olesen Larsen S; Nielsen CT; Duus K; Jacobsen S; Houen G
    PLoS One; 2015; 10(9):e0138753. PubMed ID: 26402865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.